Refractory dissecting cellulitis of the scalp treated with adalimumab

Journal of Drugs in Dermatology

Volumn 7, Issue 10, 2008, Pages 981-983

  Sukhatme, Smita V ^a   Lenzy, Yolanda M ^b   Gottlieb, Alice B ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ISOTRETINOIN; KERATOLYTIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CASE REPORT; CELLULITIS; DRUG POTENTIATION; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SCALP; SCAR; SKIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CELLULITIS; CICATRIX; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; SCALP; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59049086156     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J. 2003;9:8.
2. Glass LF, Berman B, Laub D. Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser. J Dermatol Surg Oncol. 1989;15:673-676. (Pubitemid 19172507)
3. Boyd AS, Binhlam JQ. Use of an 800-nm pulsed-diode laser in the treatment of recalcitrant dissecting cellulitis of the scalp. Arch Dermatol. 2002;138:1291-1293.
4. Chicarilli ZN. Follicular occlusion triad: Hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg. 1987;18:230-237. (Pubitemid 17035664)
5. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-326.
6. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97:2155-2156.
7. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540-1542. (Pubitemid 37523071)
8. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16:58-61. (Pubitemid 40283328)
9. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155:1105-1107. (Pubitemid 44564546)
10. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628. (Pubitemid 46400174)
11. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287-1291.
12. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007 Mar;32(2):204-5. (Pubitemid 46233031)
13. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008 Feb;158(2):370-4.
14. Cusack C, Buckley C. Etanercept: Effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006 Apr;154(4):726-9. (Pubitemid 43374099)
15. Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006 Nov 20;5:e8.
16. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008 Mar;158(3):567-72. (Pubitemid 351239170)
17. Zangrilli A, Esposito M, Mio G, et al. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2008 Mar 7.
18. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006 Sep;142(9):1110-2. (Pubitemid 44414393)
19. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol. 2006 Jul;55(1):163-4.
20. Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs. 2005 Apr;17(2):97-107.
21. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005 Dec;9(6):296-302. (Pubitemid 44491079)
22. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005 May;152(5):1059-61. (Pubitemid 40704955)
23. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007 Mar;143(3):306-8. (Pubitemid 46465720)
24. Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007 Dec;157(6):1274-5.
25. Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003 Jan;48(1):68-75. (Pubitemid 36091536)
26. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly downregulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005 Aug 15;175(4):2721-9. (Pubitemid 41113889)